@viggysinternet: On 17 May 2026, the World Health Organisation (WHO) declared that the current Ebola virus disease outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a ‘public health emergency of international concern’. As of 9 July, 600 people had died and 1,759 had been infected, according to figures from the DRC’s National Institute of Public Health (INSP). Unfortunately, no effective treatment or vaccine against the Bundibugyo virus is currently available. To address this health crisis, WHO experts have recommended evaluating the effectiveness of several therapeutic and preventive measures. In order to prevent the onset of the disease among high-risk contacts and to strengthen protection for the population, priority has been given to the antiviral obeldesivir. This experimental drug, administered orally and developed by Gilead Sciences, has shown efficacy against several filoviruses, including the Bundibugyo virus, in pre-clinical models. “Prevention is essential to stopping this outbreak and protecting those at highest risk of infection. If successful, the EBO-PEP trial could establish post-exposure prophylaxis as a game-changing approach for preventing Ebola disease among people who have been exposed to the virus. Combined with strong community engagement and effective contact tracing, it could provide an important new way to save lives and help bring outbreaks under control,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “An Ebola exposure is a moment of fear for a health worker, a family and a community. EBO-PEP gives us a critical opportunity to act before exposure becomes disease. Africa CDC has pledged USD 1 million to the trial. The further USD 5 million committed by DRC and South Africa during the 2 July meeting in Kinshasa between President Félix Tshisekedi and President Cyril Ramaphosa, African Union Champion for Pandemic Prevention, Preparedness and Response, shows what African political leadership can deliver. Our scientists are supporting the study’s coordination and field teams in Bunia. We now call on partners to close the remaining financing gap and prepare for rapid, equitable access if obeldesivir proves safe and effective. Those carrying the greatest risk must be among the first to benefit,” said H.E. Dr Jean Kaseya, Director General of Africa CDC. The National Institute for Biomedical Research (INRB) in Kinshasa, the ANRS Emerging infectious diseases / Inserm and the NGO ALIMA, alongside all their partners, are launching EBO-PEP, the first clinical trial to assess the efficacy of post-exposure prophylaxis (PEP) with the antiviral obeldesivir against the current Bundibugyo Ebola virus outbreak. The trial begins on 14 July 2026 in the Democratic Republic of the Congo and Uganda. link to full report below #ebola #cycosplora #covid #maskup video description: black person in woods as images of information on infectious diseases overlay video. hes wearing a v-flex n95 duckbill respirator

vignette♾️💫

Open In TikTok:

Region: US

Tuesday 14 July 2026 15:58:58 GMT